Effects of Dietary Energy Density on Serum Adipocytokine Levels in Diabetic Women

Abstract

This study was aimed to assess the effect of dietary energy density (kcal/g) on serum levels of adipocytokines of type 2 diabetic women. In this randomized parallel design clinical trial, a total of 60 diabetic women (aged 30–60 years; BMI>25 kg/m²) were assigned to consume either a low-energy dense (LED) (65% of energy from carbohydrates and 25% from fats), normal-energy dense (NED) (60% from carbohydrates, 30% from fats), or high-energy dense (HED) diet (55% from carbohydrates and 35% from fats) for 8 weeks. The low-energy dense diet was rich in fruits, vegetables, whole grains, and water, while the high-energy dense diet was rich in fats and oils and limited in fruits and vegetables as compared with the normal-dense diet. At baseline and at the end of intervention fasting blood samples were taken to assess metabolic profile. Women in the LED group consumed significantly more dietary fiber (p<0.001), fruits (p<0.001) and vegetables (p<0.001) than those in the NED and HED groups. We failed to find a significant effect of dietary energy density (kcal/g) on serum adiponectin and visfatin levels. Even the within-group changes in serum adiponectin and visfatin levels were not significant. Consumption of LED and NED diets resulted in a significant increase in serum chemerin levels (p=0.04). Comparison of mean changes of serum chemerin levels across 3 groups revealed a significant difference (p=0.04). Our study provides evidence indicating that consumption of HED diet for 8 weeks among diabetic patients prevented the increase in serum chemerin levels compared with LED and NED diets. Furthermore, we found no significant effect of dietary energy density (kcal/g) on serum adiponectin and visfatin concentrations in the current study.

Key words

energy density - diet - diabetes - adipocytokines

• References

• 1 Hlatky MA, Chung SC, Escobedo J, Hillegass WB, Melsop K, Rogers W, Brooks MM. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am Heart J 2010; 159: 292-300
• 2 Annuzzi G, Bozzetto L, Patti L, Santangelo C, Giacco R, Di Marino L, De Natale C, Masella R, Riccardi G, Rivellese AA. Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. Metabolism 2010; 59: 567-574
• 3 Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700
• 4 Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-1751
• 5 Pickup JC. Inflammatory markers and type 2 diabetes. Diabetes Technol Ther 2006; 8: 1-6
• 6 Ortega Martinez de Victoria E, Xu X, Koska J, Francisco AM, Scalise M, Ferrante Jr AW, Krakoff J. Macrophage content in subcutaneous adipose tissue: associations with adiposity, inflammatory markers, and whole-body insulin action in healthy Pima Indians. Diabetes 2009; 58: 385-393
• 7 Zhu J, Schott M, Liu R, Liu C, Shen B, Wang Q, Mao X, Xu K, Wu X, Schinner S, Papewalis C, Scherbaum WA, Liu C. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res 2008; 40: 801-805
• 8 ZuSinger JR, Palmas W, Teresi J, Weinstock R, Shea S, Luchsinger JA. Adiponectin and all-cause mortality in elderly people with type 2 diabetes. Diabetes Care 2012; 35: 1858-1863
• 9 Daimon M. Decreased serum levels of adiponectin as a risk factor for development of type 2 diabetes. Nippon Rinsho 2005; 63: 642-645
• 10 Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, Boden G, Li L. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med 2010; 58: 883-886
• 11 Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Erdem G, Gok M, Bingol N, Kilic S, Ozgurtas T, Bingol S. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29
• 12 Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Sasaki S. Chemerin – a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007; 362: 1013-1018
• 13 Wang J, Luben R, Khaw KT, Bingham S, Wareham NJ, Forouhi NG. Dietary energy density predicts the risk of incident type 2 diabetes: the European Prospective Investigation of Cancer (EPIC)-Norfolk Study. Diabetes Care 2008; 31: 2120-2125
• 14 Rolls BJ. The relationship between dietary energy density and energy intake. Physiol Behav 2009; 97: 609-615
• 15 Esmaillzadeh A, Azadbakht L. Dietary energy density and the metabolic syndrome among Iranian women. Eur J Clin Nutr 2011; 65: 598-605
• 16 Esmaillzadeh A, Boroujeni HK, Azadbakht L. Consumption of energy-dense diets in relation to cardiometabolic abnormalities among Iranian women. Public Health Nutr 2012; 15: 868-875
• 17 Mendoza JA, Drewnowski A, Christakis DA. Dietary energy density is associated with obesity and the metabolic syndrome in U.S. adults. Diabetes Care 2007; 30: 974-979
• 18 Murakami K, Sasaki S, Takahashi Y, Uenishi K. Japan Diet Stud Study NBG . Dietary energy density is associated with body mass index and waist circumference, but not with other metabolic risk factors, in free-living young Japanese women. Nutrition 2007; 23: 798-806
• 19 Summer SS, Brehm BJ, Benoit SC, D’Alessio DA. Adiponectin Changes in Relation to the Macronutrient Composition of a Weight-Loss Diet. Obesity 2011; 19: 2198-2204
• 20 Paniagua JA, Gallego de la Sacristana A, Romero I, Vidal-Puig A, Latre JM, Sanchez E, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007; 30: 1717-1723
• 21 Esmaillzadeh A, Azadbakht L. Legume consumption is inversely associated with serum concentrations of adhesion molecules and inflammatory biomarkers among Iranian women. J Nutr 2012; 142: 334-339
• 22 de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Romero E. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008; 24: 517-521
• 23 Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O’Brien WL, Bassett Jr DR, Schmitz KH, Emplaincourt PO, Jacobs Jr DR, Schmitz KH, Emplaincourt PO, Jacobs Jr DR, Leon AS. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32: 498-504
• 24 Fagerberg B, Kellis D, Bergstrom G, Behre CJ. Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women. J Intern Med 2011; 269: 636-643
• 25 Nasseri E, Keshavarz SA, Hosseini S, Dorosty AR, Chamari M. Relationship between visceral adiposity and plasma adiponectin concentration: effect of weight loss. Iran J Public Health 2008; 37: 35-41
• 26 Roman AA, Parlee SD, Sinal CJ. Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine 2012; 42: 243-251
• 27 Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Goke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009; 161: 339-344